CoChat

TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury

Open access

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Abstract

Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration. In the brain, TREM2 is predominantly expressed in microglia. Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques. We here investigate the consequences of TREM2 loss of function on the microglia transcriptome. Among the differentially expressed messenger RNAs in wild-type and Trem2-/- microglia, gene clusters are identified which represent gene functions in chemotaxis, migration and mobility. Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels. In an ex vivo organotypic brain slice assay, absence of TREM2 reduces the distance migrated by microglia. Moreover, migration towards defined chemo-attractants is reduced upon ablation of TREM2 and can be rescued by TREM2 re-expression. In vivo, microglia lacking TREM2 migrate less towards injected apoptotic neurons, and outgrowth of microglial processes towards sites of laser-induced focal CNS damage in the somatosensory cortex is slowed. The apparent lack of chemotactic stimulation upon depletion of TREM2 is consistent with a stable expression profile of genes characterizing the homoeostatic signature of microglia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/embr.201743922

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 355

Metadata

Authors
Mazaheri, F., Snaidero, N., Kleinberger, G., Madore, C., Daria, A., Werner, G., Krasemann, S., Capell, A., Trümbach, D., Wurst, W., Brunner, B., Bultmann, S., Tahirovic, S., Kerschensteiner, M., Misgeld, T., Butovsky, O., & Haass, C.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • LMU Klinikum (DE)
  • Munich Cluster for Systems Neurology (DE)
  • Brigham and Women's Hospital (US)
  • Ludwig-Maximilians-Universität München (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Helmholtz Munich (DE)
  • Center for Integrated Protein Science Munich (DE)
Corresponding author
Haass, Christian
Venue
The EMBO Reports
Published
2017-05-08
Volume
18
Issue
7
Pages
1186-1198
ISSN
  • 1469-221X (ISSN-L)
  • 1469-3178
OpenAlex
W2612288104
Cited by
351
References
69
Citations by year
2026: 37 · 2025: 34 · 2024: 39 · 2023: 35 · 2022: 40 · 2021: 41 · 2020: 44 · 2019: 34 · 2018: 36 · 2017: 10
FWCI
17.44
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • DZNE Pub (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (EXC 1010, Mi 694/4‐1(SPP1710)/7‐1/8‐1)
  • European Union's Seventh Framework Program (FP7/2007–2013)
  • ERC (321366, 616791)
  • Cure Alzheimer's
  • Center for Integrated Protein Science Munich (EXC 114)
  • Hans‐and‐Ilse‐Breuer Foundation
  • German Science Foundation Collaborative Research Centre (870)
  • Helmholtz Portfolio Theme “Supercomputing and Modeling for the Human Brain”
  • NIH‐NINDS (1R01NS088137)
  • NIA (1R01AG051812)
  • National Multiple Sclerosis Society (5092A1)
  • Amyotrophic Lateral Sclerosis Association (ALSA2087)
  • Nancy Davis Foundation
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
TREM2, microglia, chemotaxis, microglial migration, neuronal injury, loss of function, microglial transcriptome, Alzheimer's disease, frontotemporal lobar degeneration, somatosensory cortex, neurodegeneration
MeSH terms
Loss of Function Mutation, Alzheimer Disease, Cells, Cultured, Chemotaxis, Humans, Membrane Glycoproteins, Neurons, Phagocytosis, Receptors, Immunologic, Microglia, Neurodegenerative Diseases, Gene Expression Profiling, Myeloid Cells, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. https://app.cochat.ai/papers/10.15252/embr.201743922
The paper
Mazaheri, F., Snaidero, N., Kleinberger, G., Madore, C., Daria, A., Werner, G., Krasemann, S., Capell, A., Trümbach, D., Wurst, W., Brunner, B., Bultmann, S., Tahirovic, S., Kerschensteiner, M., Misgeld, T., Butovsky, O., & Haass, C. (2017). TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. The EMBO Reports. https://doi.org/10.15252/embr.201743922

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.